Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Sep 11, 2023 8:11pm
181 Views
Post# 35630500

Medical device ethics and compliance conference

Medical device ethics and compliance conference

 

 

https://www.pharmacongress.com/wp-content/themes/ipc/brochure/2023Pharma-agenda-20230822.pdf

Both Lafond and Vince (contracted by THTX) will be speaking at a conference with the agenda medical device ethics and compliance.

 

"Mini Summit 36: Outsourced Compliance Programs:

How to Make them Work?

As corporate budgets shrink amid global economic belt-tightening, life science com-panies, especially start-up companies looking to launch their first or second product, struggle to strike the right balance between economic efficiency and compliance effectiveness. To strike that balance, many companies have turned to outsourcing their compliance function as the right solution. With the COVID pandemic making virtual support a "New Normal" an outsourced compliance solution is more viable than ever. The latest updated Department of Justice Compliance Program Guidance clearly recognizes this as an option. Listen to experienced practitioners and in-house counsel who have implemented this option. They will share their views on how best to do so to be truly effective and cost-efficient from both a legal/compliance and business perspective.

9:00 am

Introduction, Discussion and Q&A

Jocelyn Lafond, LLB, LLM, Vice President, General Counsel and Corporate Secretary, Theratechnologies, Montreal, Quebec, Canada

L. Stephan Vince, JD, LLM, MBA, President and Chief Executive Officer, TRESTLE Compliance; Former Sr. Vice President and Chief Compliance Officer, Warner Chilcot; Former Vice President, Ethics and Compliance Officer, TAP Pharmaceutical, Boston, MA (Moderator)".

 

<< Previous
Bullboard Posts
Next >>